Organization

Precision BioSciences, Inc.

About

Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life with its proprietary ARCUS genome editing platform – a versatile genome editing platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing therapy candidates designed to cure genetic and infectious diseases where no adequate treatments exist.

Overview

Founded 2006
Type Public
Location North Carolina, USA

Stock

DTIL $1.31 -3.68% $(0.05)

Latest News

Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus Aug 10, 2022 Zacks Investment Research Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for...
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss Aug 10, 2022 Zacks Investment Research Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired...
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates Aug 09, 2022 Zacks Investment Research Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings Aug 09, 2022 Zacks Investment Research Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for...
Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates Aug 08, 2022 Zacks Investment Research Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to...